EXTON, Pa., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that company management will host a webcast to discuss the company’s recently announced acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. The webcast will be held at 11:00 a.m. Eastern on Thursday, August 19, 2021.
Recro Pharma takes manufacturing business ‘bi-coastal’ with $50M deal for CDMO Irisys
Irisys LLC, a pharmaceutical contract manufacturing and development organization (CDMO), has announced its third contract for production and manufacturing in partnership with TFF Pharmaceuticals Inc., a clinical-stage biopharmaceutical company located in Austin, TX. Most recently, TFF Pharmaceuticals contracted with Irisys to manufacture an inhalable lung medication with the potential to treat COVID-19.